Events in December, 2018
Abstract deadline: Keystone Symposia - Diabetes: Innovations, Outcomes and Personalized Therapies (X3) joint with the meeting on Unraveling the Secrets of Kidney Disease (X4)
Location: Whistler, British Columbia, Canada
Dec. 4, 2018
THE NEW YORK ACADEMY OF SCIENCES: PHAGOCYTES IN HEALTH AND DISEASE
This symposium will bring together leaders in the fields of immunology, cancer biology and tissue regeneration to highlight emerging roles for phagocytes in health and disease and develop new conceptual frameworks to integrate macrophage and dendritic cell functions with mammalian development, physiology and tissue biology.
Location: New York, NY, USA
More information: https://www.nyas.org/events/2018/phagocytes-in-health-and-disease/
Dec. 8-12, 2018
ASCB/EMBO 2018 Meeting (Meet dkNET team!)
Meet dkNET team at the 2018 ASCB|EMBO Meeting. ASCB/EMBO meeting focuses on cell biology as the fundamental basis of biology and exploring more specialized fields, such as neurobiology and stem cell biology.
Location: San Diego, CA USA
More information: https://ascb-embo2018.ascb.org
Dec. 12-14, 2018
NIDDK Meeting: Collaborating for the Advancement of Interdisciplinary Research in Benign Urology
The purpose of the Collaborating for the Advancement of Interdisciplinary Research in Benign Urology meeting is to bring together the Directors of the O?Brien Urology Centers and their project directors, the Directors of the Planning Centers for Interdisciplinary Research in Benign Urology, and the Directors for the Multidisciplinary K12 Urologic Research (KURe) Career Development Program and their fellows. This meeting will promote interactions between Centers and Programs and the sharing of resources.
Location: Ellicott City, MD, USA
More information: https://www.niddk.nih.gov/news/meetings-workshops/2018/urology-program-directors-meeting-2018
Dec. 15, 2018
Feedback Submission Deadline: Strategic Plan for NIH Nutrition Research
The NIH Nutrition Research Task Force (NRTF) is currently developing the Strategic Plan for NIH Nutrition Research. The plan emphasizes cross-cutting, innovative opportunities to advance nutrition research across a wide range of areas, from basic science to experimental design to training. These opportunities complement and enhance ongoing research efforts across NIH to improve health and to prevent or combat diseases and conditions affected by nutrition. The NRTF invites you to review the draft plan.
More information: https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/strategic-plan-nih-nutrition-research#NIHnutritionresearch
Funding opportunities information and deadlines in December, 2018
Dec. 6, 2018
NIDDK Funding Opportunity Application Due Date: Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for projects to determine the mechanisms underlying the contribution of these risk-associated genes and their variants for Type 1 Diabetes (T1D). The purpose is to accelerate the discovery of function of the causal genes and variants that influence the risk for disease.
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-005.html
Dec. 6, 2018
NIDDK Funding Opportunity Application Due Date: Clinical, Behavioral and Physiological Research Testing Current and Novel Closed Loop Systems (R01 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing clinical trials to test a highly reliable, wearable/implantable, portable, and easy to operate system linking continuous glucose monitoring and pancreatic hormone delivery in a closed loop system. This research is also intended to study behavioral and physiological aspects of relevance to the use and adoption of these systems. The main goal of this FOA is to improve glucose control and quality of life of patients with type 1 diabetes. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-023.html
Dec. 6, 2018
NIDDK Funding Opportunity Application Due Date: Immune System Engineering For Targeted Tolerance in Type 1 Diabetes (R01 Clinical Trial Not Allowed)
Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomaterials engineering, are especially encouraged.
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-020.html
Dec. 6, 2018
NIDDK Funding Opportunity Application Due Date: Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (R01 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing clinical studies of the use of current and emerging technologies for monitoring of blood glucose and insulin administration in older adults. (aged 65 years or older) Older adults may have increased vulnerability to hypoglycemia, cognitive impairment and/or multiple co-morbidities which may affect the risks and benefits of these technologies in this population. This research is intended to improve health, glucose control and quality of life of older patients with type 1 diabetes Only human studies will be considered responsive to this FOA; applications involving animal or invitro studies are not responsive to this FOA.
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-024.html
Dec. 6, 2018
NIDDK Funding Opportunity Application Due Date: Understanding Skeletal Effects of Type 1 Diabetes (R01 Clinical Trial Optional)This Funding Opportunity Announcement (FOA) invites applications for studies to understand the effects of type 1 diabetes (T1D) on bone mass and quality and/or fracture risk. Researchers may propose investigations in newly recruited subjects or using subjects and/or samples from ongoing clinical studies of individuals with for T1D.
Dec. 6, 2018
NIDDK Funding Opportunity Application Due Date: The Characterization and Discovery of Novel Autoantigens and Epitopes in Type 1 Diabetes (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research aimed at the characterization and discovery of neoantigens and neoepitopes in type 1 diabetes. These include the characterization of the humoral and cell mediated autoimmune responses elicited by these neoepitopes and neoantigens and their role in the etiology and pathophysiology of type 1 diabetes. These studies should be integrated with the present knowledge of established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8T).
Dec. 11, 2018
NIDDK Funding Opportunity Letter of Intent Due Date: Human Islet Research Network - Consortium on Human Islet Biomimetics (HIRN-CHIB) (UG3/UH3 Clinical Trial Not Allowed)
This FOA invites new applications to participate in the Human Islet Research Network-Consortium on Human Islet Biomimetics (HIRN-CHIB). NIDDK will support the development of a microphysiological system (MPS) that allows the study of interactions between primary human islets or assembled islet spheroids (organoids made up of human beta/alpha/delta/other cells) and immune cells within a 3D microenvironment to mimic aspects of the autoimmune process and its regulation. The ultimate goal will be to create an in vitro human disease model(s) that could recapitulate some aspects of the complex pathophysiology of Type 1 diabetes (T1D), by using T1D patient-derived islets (created using induced pluripotent stem cells (iPSCs) combined with autologous immune components. CHIB is already part of HIRN, whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans.
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-011.html